BioCentury | Oct 30, 2020
Deals

Via takeout of Atlas-grown optogenetic play for $150M up front, Novartis adds to gene therapy arsenal

...newco launched in June 2019 with $21 million in a series A round from Atlas Venture, Mission BioCapital...
...which will be known as Vedere, retains its predecessor’s management and will be backed by Atlas Venture, Mission BioCapital...
BioCentury | Oct 17, 2020
Deals

Oct. 16 Quick Takes: Dren Bio’s $60M series A; plus Roche, Synairgen, Astellas-iota and more

...with participation from existing investors 8VC and Mission BioCapital...
BioCentury | May 13, 2020
Emerging Company Profile

QurAlis taking three ALS programs toward clinic with $42M series A

...development of three therapies to treat amyotrophic lateral sclerosis and genetically-driven frontotemporal dementia. Polaris Partners, Mission BioCapital...
...having these conversations, not just with other companies but also academic groups” around its use. Mission BioCapital...
...its LS Polaris Innovation Fund; INKEF’s Roel Bulthuis; DDF’s Jonathan Behr; and Droia’s Luc Dochez. Mission BioCapital’s...
Items per page:
1 - 3 of 3
BioCentury | Oct 30, 2020
Deals

Via takeout of Atlas-grown optogenetic play for $150M up front, Novartis adds to gene therapy arsenal

...newco launched in June 2019 with $21 million in a series A round from Atlas Venture, Mission BioCapital...
...which will be known as Vedere, retains its predecessor’s management and will be backed by Atlas Venture, Mission BioCapital...
BioCentury | Oct 17, 2020
Deals

Oct. 16 Quick Takes: Dren Bio’s $60M series A; plus Roche, Synairgen, Astellas-iota and more

...with participation from existing investors 8VC and Mission BioCapital...
BioCentury | May 13, 2020
Emerging Company Profile

QurAlis taking three ALS programs toward clinic with $42M series A

...development of three therapies to treat amyotrophic lateral sclerosis and genetically-driven frontotemporal dementia. Polaris Partners, Mission BioCapital...
...having these conversations, not just with other companies but also academic groups” around its use. Mission BioCapital...
...its LS Polaris Innovation Fund; INKEF’s Roel Bulthuis; DDF’s Jonathan Behr; and Droia’s Luc Dochez. Mission BioCapital’s...
Items per page:
1 - 3 of 3